Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 59(6): 2381-95, 2016 Mar 24.
Article in English | MEDLINE | ID: mdl-26859603

ABSTRACT

Opioid receptor screening of a conopeptide library led to a novel selective κ-opioid agonist peptide (conorphin T). Intensive medicinal chemistry, guided by potency, selectivity, and stability assays generated a pharmacophore model supporting rational design of highly potent and selective κ-opioid receptor (KOR) agonists (conorphins) with exceptional plasma stability. Conorphins are defined by a hydrophobic benzoprolyl moiety, a double arginine sequence, a spacer amino acid followed by a hydrophobic residue and a C-terminal vicinal disulfide moiety. The pharmacophore model was supported by computational docking studies, revealing receptor-ligand interactions similar to KOR agonist dynorphin A (1-8). A conorphin agonist inhibited colonic nociceptors in a mouse tissue model of chronic visceral hypersensitivity, suggesting the potential of KOR agonists for the treatment of chronic abdominal pain. This new conorphine KOR agonist class and pharmacophore model provide opportunities for future rational drug development and probes for exploring the role of the κ-opioid receptor.


Subject(s)
Analgesics/pharmacology , Conus Snail/chemistry , Dynorphins/pharmacology , Receptors, Opioid, kappa/agonists , Abdominal Pain/drug therapy , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclic AMP/biosynthesis , High-Throughput Screening Assays , Hypersensitivity/drug therapy , Male , Mice , Mice, Inbred C57BL , Molecular Docking Simulation , Neurons, Afferent/drug effects , Peptide Library , Rats , Rats, Wistar , Structure-Activity Relationship
2.
Eur J Med Chem ; 97: 202-13, 2015 Jun 05.
Article in English | MEDLINE | ID: mdl-25974856

ABSTRACT

An increasing number of macrocyclic peptides that cross biological membranes are being reported, suggesting that it might be possible to develop peptides into orally bioavailable therapeutics; however, current understanding of what makes macrocyclic peptides cell permeable is still limited. Here, we synthesized 62 cyclic hexapeptides and characterized their permeability using in vitro assays commonly used to predict in vivo absorption rates, i.e. the Caco-2 and PAMPA assays. We correlated permeability with experimentally measured parameters of peptide conformation obtained using rapid methods based on chromatography and nuclear magnetic resonance spectroscopy. Based on these correlations, we propose a model describing the interplay between peptide permeability, lipophilicity and hydrogen bonding potential. Specifically, peptides with very high permeability have high lipophilicity and few solvent hydrogen bond interactions, whereas peptides with very low permeability have low lipophilicity or many solvent interactions. Our model is supported by molecular dynamics simulations of the cyclic peptides calculated in explicit solvent, providing a structural basis for the observed correlations. This prospective exploration into biomarkers of peptide permeability has the potential to unlock wider opportunities for development of peptides into drugs.


Subject(s)
Molecular Dynamics Simulation , Peptides, Cyclic/pharmacokinetics , Caco-2 Cells , Humans , Models, Biological , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/chemistry , Quantitative Structure-Activity Relationship
3.
Proc Natl Acad Sci U S A ; 111(49): 17504-9, 2014 Dec 09.
Article in English | MEDLINE | ID: mdl-25416591

ABSTRACT

Enhancing the oral bioavailability of peptide drug leads is a major challenge in drug design. As such, methods to address this challenge are highly sought after by the pharmaceutical industry. Here, we propose a strategy to identify appropriate amides for N-methylation using temperature coefficients measured by NMR to identify exposed amides in cyclic peptides. N-methylation effectively caps these amides, modifying the overall solvation properties of the peptides and making them more membrane permeable. The approach for identifying sites for N-methylation is a rapid alternative to the elucidation of 3D structures of peptide drug leads, which has been a commonly used structure-guided approach in the past. Five leucine-rich peptide scaffolds are reported with selectively designed N-methylated derivatives. In vitro membrane permeability was assessed by parallel artificial membrane permeability assay and Caco-2 assay. The most promising N-methylated peptide was then tested in vivo. Here we report a novel peptide (15), which displayed an oral bioavailability of 33% in a rat model, thus validating the design approach. We show that this approach can also be used to explain the notable increase in oral bioavailability of a somatostatin analog.


Subject(s)
Amides/chemistry , Drug Design , Magnetic Resonance Spectroscopy , Peptides/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Caco-2 Cells , Chromatography, Liquid , Humans , Hydrogen Bonding , Mass Spectrometry , Methylation , Peptides/chemical synthesis , Permeability , Protein Binding , Protein Conformation , Protein Interaction Mapping , Rats , Rats, Wistar , Solvents/chemistry , Technology, Pharmaceutical/methods , Temperature
4.
ACS Med Chem Lett ; 5(10): 1148-51, 2014 Oct 09.
Article in English | MEDLINE | ID: mdl-25313329

ABSTRACT

Development of peptide-based drugs has been severely limited by lack of oral bioavailability with less than a handful of peptides being truly orally bioavailable, mainly cyclic peptides with N-methyl amino acids and few hydrogen bond donors. Here we report that cyclic penta- and hexa-leucine peptides, with no N-methylation and five or six amide NH protons, exhibit some degree of oral bioavailability (4-17%) approaching that of the heavily N-methylated drug cyclosporine (22%) under the same conditions. These simple cyclic peptides demonstrate that oral bioavailability is achievable for peptides that fall outside of rule-of-five guidelines without the need for N-methylation or modified amino acids.

5.
Chem Biol ; 21(2): 284-94, 2014 Feb 20.
Article in English | MEDLINE | ID: mdl-24440079

ABSTRACT

Disrupting the binding interaction between proprotein convertase (PCSK9) and the epidermal growth factor-like domain A (EGF-A domain) in the low-density lipoprotein receptor (LDL-R) is a promising strategy to promote LDL-R recycling and thereby lower circulating cholesterol levels. In this study, truncated 26 amino acid EGF-A analogs were designed and synthesized, and their structures were analyzed in solution and in complex with PCSK9. The most potent peptide had an increased binding affinity for PCSK9 (KD = 0.6 µM) compared with wild-type EGF-A (KD = 1.2 µM), and the ability to increase LDL-R recycling in the presence of PCSK9 in a cell-based assay.


Subject(s)
Peptides/metabolism , Proprotein Convertases/metabolism , Receptors, LDL/metabolism , Serine Endopeptidases/metabolism , Amino Acid Sequence , Binding Sites , Cell Line , Cholesterol/metabolism , Epidermal Growth Factor/chemistry , Fluorescence Resonance Energy Transfer , Humans , Molecular Dynamics Simulation , Molecular Sequence Data , Mutagenesis , Peptides/chemical synthesis , Peptides/chemistry , Proprotein Convertase 9 , Proprotein Convertases/chemistry , Proprotein Convertases/genetics , Protein Binding , Protein Structure, Secondary , Protein Structure, Tertiary , Serine Endopeptidases/chemistry , Serine Endopeptidases/genetics
6.
J Med Chem ; 52(22): 6991-7002, 2009 Nov 26.
Article in English | MEDLINE | ID: mdl-19860431

ABSTRACT

Norepinephrine (NE) amplifies the strength of descending pain inhibition, giving inhibitors of spinal NET clinical utility in the management of pain. chi-MrIA isolated from the venom of a predatory marine snail noncompetitively inhibits NET and reverses allodynia in rat models of neuropathic pain. An analogue of chi-MrIA has been found to be a suitable drug candidate. On the basis of the NMR solution structure of this related peptide, Xen2174 (3), and structure-activity relationships of analogues, a pharmacophore model for the allosteric binding of 3 to NET is proposed. It is shown that 3 interacts with NET predominantly through amino acids in the first loop, forming a tight inverse turn presenting amino acids Tyr7, Lys8, and Leu9 in an orientation allowing for high affinity interaction with NET. The second loop interacts with a large hydrophobic pocket within the transporter. Analogues based on the pharmacophore demonstrated activities that support the proposed model. On the basis of improved chemical stability and a wide therapeutic index, 3 was selected for further development and is currently in phase II clinical trials.


Subject(s)
Conotoxins/chemistry , Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors , Pain/drug therapy , Peptides/chemistry , Peptides/pharmacology , Allosteric Regulation , Amino Acid Sequence , Animals , COS Cells , Chlorocebus aethiops , Drug Discovery , Drug Stability , Humans , Hydrogen Bonding , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Conformation , Norepinephrine Plasma Membrane Transport Proteins/chemistry , Norepinephrine Plasma Membrane Transport Proteins/metabolism , Pain/metabolism , Peptides/adverse effects , Peptides/metabolism , Rats , Structure-Activity Relationship
7.
PLoS One ; 2(6): e515, 2007 Jun 13.
Article in English | MEDLINE | ID: mdl-17565368

ABSTRACT

Little is known about the molecular basis of somatosensory mechanotransduction in mammals. We screened a library of peptide toxins for effects on mechanically activated currents in cultured dorsal root ganglion neurons. One conopeptide analogue, termed NMB-1 for noxious mechanosensation blocker 1, selectively inhibits (IC(50) 1 microM) sustained mechanically activated currents in a subset of sensory neurons. Biotinylated NMB-1 retains activity and binds selectively to peripherin-positive nociceptive sensory neurons. The selectivity of NMB-1 was confirmed by the fact that it has no inhibitory effects on voltage-gated sodium and calcium channels, or ligand-gated channels such as acid-sensing ion channels or TRPA1 channels. Conversely, the tarantula toxin, GsMTx-4, which inhibits stretch-activated ion channels, had no effects on mechanically activated currents in sensory neurons. In behavioral assays, NMB-1 inhibits responses only to high intensity, painful mechanical stimulation and has no effects on low intensity mechanical stimulation or thermosensation. Unexpectedly, NMB-1 was found to also be an inhibitor of rapid FM1-43 loading (a measure of mechanotransduction) in cochlear hair cells. These data demonstrate that pharmacologically distinct channels respond to distinct types of mechanical stimuli and suggest that mechanically activated sustained currents underlie noxious mechanosensation. NMB-1 thus provides a novel diagnostic tool for the molecular definition of channels involved in hearing and pressure-evoked pain.


Subject(s)
Behavior, Animal/drug effects , Ion Channels/drug effects , Mechanotransduction, Cellular/drug effects , Pain/drug therapy , Peptide Fragments/pharmacology , Animals , Animals, Newborn , Cells, Cultured , Electrophysiology , Ganglia, Spinal/cytology , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Hair Cells, Auditory/cytology , Hair Cells, Auditory/drug effects , Hair Cells, Auditory/metabolism , Intercellular Signaling Peptides and Proteins , Male , Mice , Mice, Inbred C57BL , Neurons/cytology , Neurons/drug effects , Neurons/metabolism , Peptides/pharmacology , Rats , Rats, Sprague-Dawley , Spider Venoms/pharmacology
8.
J Biol Chem ; 279(34): 35326-33, 2004 Aug 20.
Article in English | MEDLINE | ID: mdl-15194691

ABSTRACT

The 19-amino acid conopeptide (rho-TIA) was shown previously to antagonize noncompetitively alpha(1B)-adrenergic receptors (ARs). Because this is the first peptide ligand for these receptors, we compared its interactions with the three recombinant human alpha(1)-AR subtypes (alpha(1A), alpha(1B), and alpha(1D)). Radioligand binding assays showed that rho-TIA was 10-fold selective for human alpha(1B)-over alpha(1A)- and alpha(1D)-ARs. As observed with hamster alpha(1B)-ARs, rho-TIA decreased the number of binding sites (B(max)) for human alpha(1B)-ARs without changing affinity (K(D)), and this inhibition was unaffected by the length of incubation but was reversed by washing. However, rho-TIA had opposite effects at human alpha(1A)-ARs and alpha(1D)-ARs, decreasing K(D) without changing B(max), suggesting it acts competitively at these subtypes. rho-TIA reduced maximal NE-stimulated [(3)H]inositol phosphate formation in HEK293 cells expressing human alpha(1B)-ARs but competitively inhibited responses in cells expressing alpha(1A)- or alpha(1D)-ARs. Truncation mutants showed that the amino-terminal domains of alpha(1B)- or alpha(1D)-ARs are not involved in interaction with rho-TIA. Alanine-scanning mutagenesis of rho-TIA showed F18A had an increased selectivity for alpha(1B)-ARs, and F18N also increased subtype selectivity. I8A had a slightly reduced potency at alpha(1B)-ARs and was found to be a competitive, rather than noncompetitive, inhibitor in both radioligand and functional assays. Thus rho-TIA noncompetitively inhibits alpha(1B)-ARs but competitively inhibits the other two subtypes, and this selectivity can be increased by mutation. These differential interactions do not involve the receptor amino termini and are not because of the charged nature of the peptide, and isoleucine 8 is critical for its noncompetitive inhibition at alpha(1B)-ARs.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Conotoxins/pharmacology , Animals , Binding Sites , Binding, Competitive , Carrier Proteins , Conotoxins/metabolism , Cricetinae , Humans , Isoleucine , Radioligand Assay
SELECTION OF CITATIONS
SEARCH DETAIL
...